The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Pentazocine has been studied across 22 research domains including 💊 Pain, 🌤️ Mood & Depression, 😴 Sleep, 🧠 Focus & Attention, ❤️ Cardiovascular. The primary research focus is 💊 Pain with 46% of studies addressing this area.
The following compounds share molecular targets with Pentazocine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Pentazocine is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.